Pembrolizumab Benefit Not Altered by KRAS Status in Nonsquamous NSCLC
January 7th 2020Two analyses presented at the 2019 ESMO Immuno-Oncology Congress provided data supporting pembrolizumab, either as monotherapy or in combination with chemotherapy, as a first-line treatment option in patients with nonsquamous non–small cell lung cancer, regardless of KRAS mutational status.
Safety of Frontline Durvalumab Combo Confirmed in Extensive-Stage Small Cell Lung Cancer
January 4th 2020Few immune-mediated adverse events were observed with frontline durvalumab plus platinum-based therapy and etoposide in patients with extensive-stage small cell lung cancer, and no treatment-emergent antidrug antibodies were elicited by the PD-L1 inhibitor, according to an analysis of the phase III CASPIAN trial reported at the 2019 ESMO Immuno-Oncology Congress.
Frontline Nivolumab/Ipilimumab Shows Clinical Benefit in NSCLC With Poor Prognosis
January 4th 2020First-line treatment with nivolumab combined with low-dose ipilimumab was safe and showed encouraging overall survival, regardless of PD-L1 expression, in patients with advanced non–small cell lung cancer, including those with comorbidities or poor ECOG performance status.
BL-8040 Plus Pembrolizumab/Chemo Provides Disease Control in Pancreatic Cancer
January 2nd 2020A triplet regimen of the CXCR4 antagonist BL-8040 plus pembrolizumab and standard chemotherapy showed promising antitumor activity in the second-line setting for the treatment of patients with metastatic pancreatic ductal adenocarcinoma.
High PD-L1 Expression, bTMB Effective Markers for Single-Agent Atezolizumab Benefit in NSCLC
December 29th 2019PD-L1-high status, determined via 3 separate immunohistochemistry assays, and blood tumor mutational burden strongly favored atezolizumab over platinum-based chemotherapy and supports the PD-L1 inhibitor as a first-line treatment option in patients with advanced non–small cell lung cancer.